Why the study?
P2X receptors participate in energy metabolism and inflammatory responses, prompting exploration of their molecular characteristics and agonist/antagonist agents as therapeutic targets in obesity and diabetes.
Key points are not available for this paper at this time.
Design
Review
P2X receptor insights remain preclinical; leaves open any cardiovascular therapeutic translation pending targeted trials.
The role of P2X ionotropic receptors in the behavior of purinergic signaling on pathophysiological processes has been widely studied. In recent years, the important participation of P2X receptors in physiological and pathological processes, such as energy metabolism, characteristic inflammatory responses of the immune system, and nociceptive activity in response to pain stimuli, has been noted. Here, we explore the molecular characteristics of the P2X receptors and the use of the different agonist and antagonist agents recently described, focusing on their potential as new therapeutic targets in the treatment of diseases with emphasis on obesity, diabetes, and some of the complications derived from these pathologies.
No takes yet. Share an insight, caveat, or question.
Cabral‐García et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: